Author : Naina mohamed pakkir maideen
Keyword : Drug interactions, cyp2c8, cyp2c9, cyp3a4, nateglinide, oatp1b1 transporter, repaglinide
Subject : Diabetes
Article Type : Review article
DOI : 10.1177/2042018818767220
Article File : Full Text PDF
Abstract : Meglitinides such as repaglinide and nateglinide are useful to treat type 2 diabetes patients who follow a flexible lifestyle. They are short-acting insulin secretagogues and are associated with less risk of hypoglycemia, weight gain and chronic hyperinsulinemia compared with sulfonylureas. Meglitinides are the substrates of cytochrome P450 (CYP) enzymes and organic anion transporting polypeptide 1B1 (OATP1B1 transporter) and the coadministration of the drugs affecting them will result in pharmacokinetic drug interactions. This article focuses on the drug interactions of meglitinides involving CYP enzymes and OATP1B1 transporter. To prevent the risk of hypoglycemic episodes, prescribers and pharmacists must be aware of the adverse drug interactions of meglitinides.
Article by : Naina Mohamed Pakkir Maideen
Article add date : 2021-12-21
How to cite : Naina mohamed pakkir maideen. (2021-December-21). Drug interactions of meglitinide antidiabetics involving cyp enzymes and oatp1b1 transporter. retrieved from https://openacessjournal.com/abstract/930